Overview

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if AP306 could work in the patients receiving maintenance hemodialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP306 lower blood phosphate levels when the participants take a fixed dose of AP306? * What medical problems do the participants have when taking AP306? The researchers will compare AP306 to a placebo (a look-alike substance that contains no drug) to see if AP306 works to treat hyperphosphatemia. The participants will: * Stop all using blood phosphate-lowering drugs, and * Take AP306 or a placebo three times a day for 12 weeks. If the participant has a blood phosphate level above a certain level, they will receive additional treatment to lower the blood phosphate level.

Phase:

PHASE2

Details

Lead Sponsor:

Alebund Pharmaceuticals

Treatments:

BID protein, human